Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Synonyms :
Class :
Brand Name :
Synonyms :
Class :
1 tablet (2.5/10 mg) orally each day. Titrate an appropriate dose to control the blood pressure.
Do not increase the dose to more than 10/80 mg per day
1 tablet (2.5/10 mg) orally each day. Titrate an appropriate dose to control the blood pressure.
Do not increase the dose to more than 10/80 mg per day
Dose Adjustments
Renal impairment-
In case of renal impairment, when CrCl<30 ml/min, decrease the dose
In case of severe renal impairment, co-administer the dose with a diuretic
Hepatic impairment-
2.5 mg based on the initial dose of amlodipine
1 tablet (2.5/10 mg) orally each day. Titrate an appropriate dose to control the blood pressure.
Do not increase the dose to more than 10/80 mg per day
Dose Adjustments
Renal impairment-
In case of renal impairment, when CrCl<30 ml/min, decrease the dose
In case of severe renal impairment, co-administer the dose with a diuretic
Hepatic impairment-
2.5 mg based on the initial dose of amlodipine
1 tablet (2.5/10 mg) orally each day. Titrate an appropriate dose to control the blood pressure.
Do not increase the dose to more than 10/80 mg per day
Dose Adjustments
Renal impairment-
In case of renal impairment, when CrCl<30 ml/min, decrease the dose
In case of severe renal impairment, co-administer the dose with a diuretic
Hepatic impairment-
2.5 mg based on the initial dose of amlodipine
may increase the adverse effect of angiotensin II receptor blockers
may increase the adverse effect of angiotensin II receptor blockers
may increase the adverse effect of angiotensin ii receptor blockers
may increase the toxic effect of angiotensin receptor II blockers
lisinopril/hydrochlorothiazideÂ
may increase the toxic effect of angiotensin receptor II blockers
may enhance the hypotensive effect when combined with sparsentan
may diminish the serum concentration when combined with angiotensin-converting enzyme inhibitors
may enhance the serum concentration when combined with lithium
may have an increased hyperkalemic effect when combined with ACE inhibitors
may have an increasingly adverse effect when combined with angiotensin-converting enzyme inhibitors
may have an increasingly adverse effect when combined with angiotensin-converting enzyme inhibitors
may have an increasingly adverse effect when combined with angiotensin-converting enzyme inhibitors
may have an increasingly adverse effect when combined with angiotensin-converting enzyme inhibitors
may have an increasingly adverse effect when combined with angiotensin-converting enzyme inhibitors
may diminish the effects of indomethacin by pharmacodynamic antagonism
may diminish the effects of indomethacin by pharmacodynamic antagonism
may diminish the effects of indomethacin by pharmacodynamic antagonism
may diminish the effects of indomethacin by pharmacodynamic antagonism
may diminish the effects of indomethacin by pharmacodynamic antagonism
it may enhance the effects when combined with lofexidine by pharmacodynamic synergism
May enhances the effects of the other by pharmacodynamic synergism
may diminish the effects of ketoprofen by pharmacodynamic antagonism
may diminish the effects of indomethacin by pharmacodynamic antagonism
may have an increasingly adverse effect when combined with sacubitril
when both the drugs are combined, there might be an increase in the anticoagulant effect
A decrease in renal function may be seen when aspirin rectal and benazepril are coadministered due to pharmacodynamic antagonism
May increase the adverse/toxic effect of NSAIDs
May increase the adverse/toxic effect of NSAIDs
May increase the adverse/toxic effect of NSAIDs
May increase the adverse/toxic effect of NSAIDs
May increase the adverse/toxic effect of NSAIDs
ACE Inhibitors may enhance the therapeutic effect of angiotensin II receptor antagonists
ACE Inhibitors may enhance the therapeutic effect of angiotensin II receptor antagonists
ACE Inhibitors may enhance the therapeutic effect of angiotensin II receptor antagonists
ACE Inhibitors may enhance the therapeutic effect of angiotensin II receptor antagonists
ACE Inhibitors may enhance the therapeutic effect of angiotensin II receptor antagonists
may enhance the bradycardic effect of beta-blockers
may enhance the bradycardic effect of beta-blockers
may enhance the bradycardic effect of beta-blockers
may enhance the bradycardic effect of beta-blockers
may enhance the bradycardic effect of beta-blockers
may enhance the hypotensive effect of ACE Inhibitors
may enhance the hypotensive effect of ACE Inhibitors
may enhance the hypotensive effect of ACE Inhibitors
may enhance the hypotensive effect of ACE Inhibitors
may reduce the therapeutic effect
may reduce the therapeutic effect
may reduce the therapeutic effect
may reduce the therapeutic effect
may reduce the therapeutic effect
It may enhance toxicity when combined with metformin by unspecified interactions mechanism
benazepril: it may decrease the excretion rate of abacavir CNS depressant
benazepril: it may decrease the excretion rate of abacavir CNS depressant
benazepril: it may decrease the excretion rate of abacavir CNS depressant
benazepril: it may decrease the excretion rate of abacavir CNS depressant
benazepril: it may decrease the excretion rate of abacavir CNS depressant
may have an increasingly adverse effect when combined with NSAIDs
benazepril: it may increase the risk or severity of CNS depression
benazepril: it may increase the risk or severity of CNS depression
benazepril: it may increase the risk or severity of CNS depression
benazepril: it may increase the risk of methemoglobinemia agents
benazepril: it may increase the risk of methemoglobinemia agents
benazepril: it may increase the risk of methemoglobinemia agents
benazepril: it may increase the risk of methemoglobinemia agents
benazepril: it may increase the risk of methemoglobinemia agents
benazepril: it may increase the antihypertensive activities of barnidipine
may increase the hypotensive effect of angiotensin-converting enzyme inhibitors
may increase the hypotensive effect of angiotensin-converting enzyme inhibitors
may increase the hypotensive effect of angiotensin-converting enzyme inhibitors
may have an increasingly adverse effect when combined with NSAIDs
benazepril: it may increase the risk or severity of QTc prolongation agents
benazepril: it may increase the risk or severity of QTc prolongation agents
benazepril: it may increase the risk or severity of QTc prolongation agents
benazepril: it may increase the risk or severity of QTc prolongation agents
benazepril: it may increase the risk or severity of QTc prolongation agents
benazepril: it may increase the risk of hyperkalemia with sulfamethoxazole
may enhance the risk of neutropenia
angiotensin-Converting Enzyme Inhibitors may enhance the hyperkalemic effect of finerenone
ACE Inhibitors may enhance the potential for allergic or hypersensitivity reactions to allopurinol
ACE Inhibitors may enhance the adverse/toxic effect of NSAIDs
ACE Inhibitors may enhance the adverse/toxic effect of NSAIDs
ACE Inhibitors may enhance the adverse/toxic effect of NSAIDs
ACE Inhibitors may enhance the adverse/toxic effect of NSAIDs
ACE Inhibitors may enhance the adverse/toxic effect of NSAIDs
may enhance the hyperkalemic effect of ACE Inhibitors
may enhance the hyperkalemic effect of ACE Inhibitors
angiotensin-converting Enzyme (ACE) inhibitors may increase the risk of adverse effects of alteplase
May enhance the toxic effects of the other by pharmacodynamic synergism
insulin degludec/insulin aspartÂ
may increase the effect of each other
may decrease the effects of the other by pharmacodynamic synergism
icatibant may reduce the antihypertensive effect of ACE inhibitors
may enhance the hyperkalemic effect of ACE Inhibitors
may enhance the hyperkalemic effect of ACE Inhibitors
may enhance the hyperkalemic effect of ACE Inhibitors
may enhance the hyperkalemic effect of ACE Inhibitors
may enhance the hyperkalemic effect of ACE Inhibitors
may increase the anti-coagulant action of anti-coagulants
may increase the nephrotoxic effect of salicylates
may have an increased allergic or hypersensitivity reactions when combined with allopurinol
may decrease the antihypertensive effect when combined with angiotensin-converting enzyme inhibitors
may have an increased orthostatic hypotensive effect when combined with angiotensin-converting enzyme inhibitors
may have an increasingly adverse effect when combined with angiotensin-converting enzyme inhibitors
may enhance the nephrotoxic effect of salicylates
may have an increased hyperkalemic effect when combined with angiotensin-converting enzyme inhibitors
drospirenone/ethinyl estradiol/levomefolateÂ
may increase the hyperkalemic effect of Drospirenone-Containing Products
choline magnesium trisalicylate
may have an increased nephrotoxic effect when combined with angiotensin-converting enzyme inhibitors
may have an increased hypotensive effect when combined with ACE inhibitors
may have an increased hypotensive effect when combined with ACE inhibitors
may have an increased hypotensive effect when combined with ACE inhibitors
may have an increased hypotensive effect when combined with angiotensin-converting enzyme inhibitors
may have an increased hypotensive effect when combined with angiotensin-converting enzyme inhibitors
procaterol: it may decrease the antihypertensive activities of benazepril
the risk of hypertension, kidney failure, and hypokalemia may be increased
the risk of hypertension, renal failure, and hyperkalemia may be increased
the risk of hypertension, kidney failure, and hypokalemia may be increased
the antihypertensive activity of benazepril may be reduced
the antihypertensive activity of benazepril may be reduced
insignificant or little drug interaction is seen due to synergistic pharmacodynamic activity
when used in combination, nabilone and benazepril both increase the effect of each other
may enhance the effects of the other by pharmacodynamic synergism
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
